Soleno Therapeutics, Inc. (NASDAQ:SLNO) CFO James H. Mackaness Sells 7,190 Shares

Soleno Therapeutics, Inc. (NASDAQ:SLNO) CFO James H. Mackaness sold 7,190 shares of the business’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $41.54, for a total transaction of $298,672.60. Following the completion of the transaction, the chief financial officer now owns 55,763 shares in the company, valued at $2,316,395.02. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Soleno Therapeutics Trading Up 5.8 %

SLNO opened at $42.03 on Thursday. Soleno Therapeutics, Inc. has a one year low of $3.69 and a one year high of $53.82. The business’s 50-day simple moving average is $43.34 and its 200-day simple moving average is $43.31.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.29). On average, analysts expect that Soleno Therapeutics, Inc. will post -2.36 earnings per share for the current year.

Institutional Trading of Soleno Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of SLNO. Cannon Global Investment Management LLC purchased a new stake in Soleno Therapeutics during the 1st quarter valued at approximately $505,000. Aspiriant LLC acquired a new position in shares of Soleno Therapeutics in the fourth quarter valued at approximately $488,000. Sei Investments Co. raised its stake in shares of Soleno Therapeutics by 22.0% during the first quarter. Sei Investments Co. now owns 12,577 shares of the company’s stock worth $538,000 after purchasing an additional 2,264 shares during the last quarter. California State Teachers Retirement System lifted its holdings in shares of Soleno Therapeutics by 33.8% during the first quarter. California State Teachers Retirement System now owns 13,780 shares of the company’s stock worth $590,000 after purchasing an additional 3,481 shares during the period. Finally, Swiss National Bank acquired a new stake in shares of Soleno Therapeutics during the fourth quarter worth $918,000. Hedge funds and other institutional investors own 97.42% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on SLNO. Robert W. Baird started coverage on shares of Soleno Therapeutics in a research report on Friday, May 10th. They set an “outperform” rating and a $72.00 price target for the company. Oppenheimer lowered their price objective on Soleno Therapeutics from $65.00 to $59.00 and set an “outperform” rating for the company in a research report on Monday, May 13th. Finally, Baird R W raised shares of Soleno Therapeutics to a “strong-buy” rating in a report on Friday, May 10th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $60.33.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.